CCR2 and rectal cancer: In patients with rectal cancer, who had the percentage of CD14+CD16+CCR2+ monocytes below 20% out of CD14+CD16+, the percentage of CD14+CD16+CCR2+ was increased after NAC (in 6 out of 7 patients tested).